This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n6http://linked.opendata.cz/resource/domain/vavai/projekt/
n18http://linked.opendata.cz/resource/domain/vavai/subjekt/
n16http://linked.opendata.cz/ontology/domain/vavai/
n14http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F26475821%3A_____%2F12%3A%230000154%21RIV13-MZ0-26475821/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n8http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F26475821%3A_____%2F12%3A%230000154%21RIV13-MZ0-26475821
rdf:type
skos:Concept n16:Vysledek
rdfs:seeAlso
http://www.ueg.eu/fileadmin/user_upload/documents/Week13/UEG_Week_2012.Final_Programme.pdf
dcterms:description
Poster: Patients with advanced stages of malignant tumors have elevated levels of circulating free DNA (cellfree DNA cfDNA) in peripheral blood. Under certain condition, examination of tumor cfDNA can substitute conventional tissue profiling from biopsies or resections with minimal invasivity. AIMS&METHODS: In the present work we demonstrate practical use of cfDNA examination in predictive KRAS testing as well as for monitoring of therapy response and the long term course of the disease. The initial group consisted of 204 patients in various confirmed stages of colon and rectal cancers undergoing either surgical treatment or chemotherapy. We have acquired tissue samples from primary and/or metastatic sites. In addition, plasma samples were acquired periodically over the course of the disease treatment. Mutation-based cfDNA detection was performed using a “classic” panel of somatic mutations covering APC, KRAS, BRAF, PIK3CA and TP53 genes. RESULTS: The cfDNA detection rates were in correlation with the disease stage. The frequency of mutation-positive cfDNA in stage IV patients was at 14% if the mutation was found only in primary tumor and 57% when the mutation was found also in the metastatic tissue. A concordance for KRAS in cfDNA and in primary tissue was 85%. The occurence or absence of cfDNA has fully coresponded with radicality of the performed operation and with positive response or resistance to the anticancer therapy. CONCLUSION: Mutation-based cfDNA monitoring is limited to patients with somatic aberrations in their tumors (72% from the group in our study). Examination of KRAS from cfDNA is an alternative with no availability of tumor tissue. Continued monitoring of cfDNA levels represents a viable tool for early prediction of disease relapse or recurrence. In patients undergoing palliative treatment the cfDNA may be used for indication of therapy resistance. Poster: Patients with advanced stages of malignant tumors have elevated levels of circulating free DNA (cellfree DNA cfDNA) in peripheral blood. Under certain condition, examination of tumor cfDNA can substitute conventional tissue profiling from biopsies or resections with minimal invasivity. AIMS&METHODS: In the present work we demonstrate practical use of cfDNA examination in predictive KRAS testing as well as for monitoring of therapy response and the long term course of the disease. The initial group consisted of 204 patients in various confirmed stages of colon and rectal cancers undergoing either surgical treatment or chemotherapy. We have acquired tissue samples from primary and/or metastatic sites. In addition, plasma samples were acquired periodically over the course of the disease treatment. Mutation-based cfDNA detection was performed using a “classic” panel of somatic mutations covering APC, KRAS, BRAF, PIK3CA and TP53 genes. RESULTS: The cfDNA detection rates were in correlation with the disease stage. The frequency of mutation-positive cfDNA in stage IV patients was at 14% if the mutation was found only in primary tumor and 57% when the mutation was found also in the metastatic tissue. A concordance for KRAS in cfDNA and in primary tissue was 85%. The occurence or absence of cfDNA has fully coresponded with radicality of the performed operation and with positive response or resistance to the anticancer therapy. CONCLUSION: Mutation-based cfDNA monitoring is limited to patients with somatic aberrations in their tumors (72% from the group in our study). Examination of KRAS from cfDNA is an alternative with no availability of tumor tissue. Continued monitoring of cfDNA levels represents a viable tool for early prediction of disease relapse or recurrence. In patients undergoing palliative treatment the cfDNA may be used for indication of therapy resistance.
dcterms:title
UTILITY OF CELL-FREE TUMOR DNA IN CLINICAL MANAGEMENT OF COLORECTAL CANCER PATIENTS UTILITY OF CELL-FREE TUMOR DNA IN CLINICAL MANAGEMENT OF COLORECTAL CANCER PATIENTS
skos:prefLabel
UTILITY OF CELL-FREE TUMOR DNA IN CLINICAL MANAGEMENT OF COLORECTAL CANCER PATIENTS UTILITY OF CELL-FREE TUMOR DNA IN CLINICAL MANAGEMENT OF COLORECTAL CANCER PATIENTS
skos:notation
RIV/26475821:_____/12:#0000154!RIV13-MZ0-26475821
n16:predkladatel
n18:ico%3A26475821
n3:aktivita
n4:P
n3:aktivity
P(NS9809)
n3:dodaniDat
n8:2013
n3:domaciTvurceVysledku
n7:6636365 n7:7377061 n7:2689677
n3:druhVysledku
n13:O
n3:duvernostUdaju
n12:S
n3:entitaPredkladatele
n14:predkladatel
n3:idSjednocenehoVysledku
176637
n3:idVysledku
RIV/26475821:_____/12:#0000154
n3:jazykVysledku
n10:eng
n3:klicovaSlova
cfDNA, colorectal cancer, KRAS, metastasis
n3:klicoveSlovo
n5:cfDNA n5:metastasis n5:KRAS n5:colorectal%20cancer
n3:kontrolniKodProRIV
[052588D82544]
n3:obor
n15:EB
n3:pocetDomacichTvurcuVysledku
3
n3:pocetTvurcuVysledku
8
n3:projekt
n6:NS9809
n3:rokUplatneniVysledku
n8:2012
n3:tvurceVysledku
Minárik, Marek Belšánová, Barbora Benešová, Lucie